Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
European Journal of Cancer(2018)
摘要
•Elderly patients with squamous non–small-cell lung cancer in an Italian expanded access programme benefited from nivolumab.•Objective response rates were similar (18–19%) for ages <65, 65–<75 and ≥75 years and all ages.•Median overall survival was reduced for ages ≥75 years (5.8 months) versus all ages (8.0 months).•Safety and tolerability with nivolumab were similar irrespective of age.
更多查看译文
关键词
Aged,Immunotherapy,Italy,Non–small-cell lung cancer
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络